In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants is going to be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase https://abbv-744-brd4-inhibition78023.prublogger.com/31257887/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described